Last updated: July 22, 2026
Allergan Sales, LLC v. Sandoz, Inc., No. 17-1499, is a U.S. patent infringement appeal matter in which Allergan challenged Sandoz’s entry posture tied to an ANDA drug product. The case posture indicates Federal Circuit review of a district-court decision in an Orange Book patent dispute, typically arising from Paragraph IV certifications under 21 U.S.C. § 355(j). No specific claims, asserted patents, PTAB issues, settlements, or merits holdings can be stated from the case caption alone.
What was Allergan v. Sandoz (17-1499) about, and which patents were at issue?
Answer: The matter is a patent infringement dispute connected to ANDA-based market entry. The caption alone does not identify the asserted patents, specific claims, product strength, dosage form, or the district court’s reasoning.
Why is “17-1499” not enough to map the asserted IP estate?
Federal Circuit docket numbers map to an appellate record, not to a single “drug + patent” package in the absence of docket metadata. Without the lower-court docket details (district court number), the asserted patent list, or the Federal Circuit opinion’s header, the following cannot be accurately enumerated:
- asserted patent numbers
- claim scope (composition vs. method of use vs. formulation)
- Orange Book listing(s) and expiry dates tied to the case
- whether the appeal was about noninfringement, invalidity, claim construction, or preliminary relief
What typical fact pattern do cases like this follow?
In Allergan v. Sandoz ANDA disputes, the underlying record usually contains:
- an ANDA filing with Paragraph IV certification against one or more Orange Book-listed patents
- a district court infringement and invalidity analysis with claim construction
- an appeal challenging Markman determinations, infringement findings, invalidity grounds, or both
How did the case reach the Federal Circuit, and what is the litigation posture of 17-1499?
Answer: No procedural disposition details (opinion, order, or remand) are available from the caption alone.
What procedural events must be present in the record?
To summarize litigation with precision, the appeal record must specify:
- the district court (court and case number)
- the decision date and judgment type (infringement, invalidity, summary judgment, JMOL, permanent injunction)
- the Federal Circuit disposition (affirmed, reversed, vacated, remanded)
- whether the appeal was consolidated with other matters (common in ANDA patent bundles)
What did the court decide in Allergan Sales, LLC v. Sandoz, Inc. (17-1499)?
Answer: The specific merits outcome cannot be stated without the Federal Circuit’s opinion or order.
Merits outcomes that matter for freedom-to-operate
Patent ANDA appeals usually turn on one or more of these:
- claim construction errors affecting infringement analysis
- anticipation/obviousness invalidity against specific references
- noninfringement based on ANDA product attributes (salt form, dosage release, impurities, method steps)
- injunction/irreparable harm findings (if that stage occurred)
Without the opinion text or the asserted claims and patents, no accurate statement can be made.
Which stage was the dispute tied to: infringement merits, injunction, or procedural motions?
Answer: The appeal number indicates a merits-level appellate posture, but the stage cannot be confirmed from the caption.
What would confirm the stage in practice?
Typical indicators in the appellate record include:
- “affirmed in part, reversed in part” on merits
- remand instructions tied to claim construction or infringement
- a separate appeal about injunction scope or contempt (less typical for a single early docket number)
Does the 17-1499 case involve Orange Book patents and Paragraph IV certifications?
Answer: The parties and the ANDA context are consistent with Paragraph IV Orange Book litigation, but the exact Orange Book listings and certification dates cannot be confirmed from the caption.
What to extract from an Orange Book listing (if the opinion were available)
In an Orange Book dispute, the record usually connects to:
- patent numbers listed in the Orange Book for the reference listed drug (RLD)
- expiration dates (including any pediatric exclusivity where applicable)
- triggers for launch eligibility (30-month stay expiration or carve-outs)
No listing identifiers are available from the caption alone.
How strong is the patent estate implied by this litigation against Sandoz?
Answer: Strength cannot be measured without asserted patents and the court’s holdings.
What “strength” analysis requires for this docket
A rigorous estate strength analysis requires:
- asserted patent families and priority dates
- remaining claim breadth after invalidity findings
- whether key claims were held invalid or merely not infringed
- whether design-around strategies were accepted
What generic launch risks did this case create for Sandoz?
Answer: The appeal posture implies that Sandoz faced ongoing entry risk tied to an infringement finding or unresolved validity issues, but the entry consequence depends on the specific dispositive outcome.
How to map launch risk to docket outcome
Launch risk varies by outcome:
- affirmed invalidity: higher risk shifts to other listed patents or non-patent regulatory barriers
- affirmed noninfringement: risk drops for the specific patent(s)
- affirmed infringement: launch is generally blocked for the relevant patent term unless overturned
- remand: outcome uncertainty persists pending district court action
No outcome details are available.
How does this dispute compare with other Allergan v. Sandoz ANDA litigations?
Answer: Comparison is not possible without identifying:
- the drug and RLD name
- the asserted patent set
- settlement terms or volume of related cases
What settlement or licensing signals exist for 17-1499?
Answer: No settlement or license terms can be stated from the caption alone.
What to look for in typical settlement disclosures
In ANDA patent litigation, settlements often reflect:
- agreed launch dates
- stipulated exclusivity carve-outs
- covenant-not-to-sue scope by patent number and jurisdiction
- use restrictions (device or formulation constraints)
Key takeaways
- Allergan Sales, LLC v. Sandoz, Inc. (17-1499) is an appellate patent dispute consistent with ANDA Paragraph IV Orange Book litigation.
- The case caption does not provide the asserted patent numbers, the drug identity, or the Federal Circuit’s disposition. Those are prerequisites for any accurate infringement/invalidity summary, patent-expiration analysis, or generic launch-risk conclusions.
FAQs
1) What patents are typically asserted in Allergan ANDA cases like 17-1499?
Patent estates vary by drug; the specific patents for 17-1499 cannot be identified from the caption alone.
2) Does a Federal Circuit appeal number (17-1499) always mean a merits decision?
It indicates appellate review, but the caption does not confirm the exact disposition type without the opinion/order.
3) How do Paragraph IV certifications usually affect entry timing in Allergan disputes?
They trigger a 30-month litigation stay and possible forfeiture/launch eligibility depending on court outcomes, but the stay mechanics for this docket require the specific ANDA and certification data.
4) Can other “Allergan v. Sandoz” cases predict the outcome of 17-1499?
Only partially; outcome depends on the specific patents, claims, and ANDA product attributes asserted in the docket record.
5) What is the typical role of claim construction in Federal Circuit ANDA patent appeals?
Claim construction can drive infringement outcomes, but the extent and impact for 17-1499 cannot be assessed without the appellate opinion.
References
- U.S. Court of Appeals for the Federal Circuit. Allergan Sales, LLC v. Sandoz, Inc., No. 17-1499 (appeal docket).
